Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > transcript of CC

<< Previous

Bullboard Posts

Next >>

Post by mingzhuon Nov 28, 2020 9:47am

811 Views

Post# 31994203

transcript of CC

https://seekingalpha.com/article/4388875-cipher-pharmaceuticals-cphrf-ceo-craig-mull-on-q3-2020-results-earnings-call-transcript

Craig Mull

Well, Peter, we were under a blackout for a good part of that. We are restricted from buying. I can tell you what our intentions are going forward. We expect to be an active buyer of our stock, subject to the regulatory requirements that we have to abide by. So we had an active – the stock is as you no doubt can see it’s very thinly traded. We would like to buy as much stock as we can.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)